Alloy is Building the World's First Fully Integrated Product Development
Organization - Read the full article
Alloy Therapeutics Expands Executive Team to Strengthen Therapeutic Discovery and Innovation for Its Partners
Biotherapeutic discovery and development expert Michael Schmidt joins as CSO to manage an expansive roadmap of technical innovation across Alloy’s platforms, services, and company formation in six modalities. Alloy’s Martin Leach is promoted to COO to expand the company’s operational excellence and discovery services capacity for partners. BOSTON, Mass. – June 28, 2023 — Alloy Therapeutics, […]
Alloy Therapeutics to Empower Drug Discovery of Lundbeck’s Biologics for Brain Health
Lundbeck expanded its collaboration with Alloy Therapeutics to leverage Alloy’s Antibody Discovery Services and SeqImmune™ sequence-first discovery workflow, building on its existing access to the ATX-Gx™ humanized transgenic mouse platform. This collaboration aims to generate highly diverse antibody repertoires and identify promising therapeutic antibody candidates for the treatment of complex brain diseases. BOSTON, Mass. – […]
Alloy Therapeutics Announces an Expansion of its Antibody Discovery Services in Conjunction with Two New Senior Vice Presidents
Kent Bondensgaard and John Lippincott joined Alloy Therapeutics as key strategic leaders to support the company’s mission of democratizing access to foundational drug discovery technologies. Their combined expertise in corporate development and clinical strategy enhances Alloy’s ability to scale its platform services and foster long-term partnerships with biotechnology and pharmaceutical innovators. Alloy Antibody Discovery Services […]
Alloy Therapeutics and Normunity Sign Multi-Program Antibody Discovery Collaboration in Immuno-Oncology
Normunity is a biotechnology company developing precision immuno-oncology therapies known as immune normalizers, designed to target novel mechanisms of immune disruption and restore the body’s natural ability to fight cancer. Through a multi-program collaboration with Alloy Therapeutics, Normunity leverages Alloy’s high-velocity, sequencing-first antibody discovery technologies to identify therapeutic antibodies against novel immuno-oncology targets, including mechanisms […]
Alloy Therapeutics Raises $42 Million Series D Financing to Accelerate Discovery Technology Development Across Biologic Modalities
Alloy Therapeutics secured $42 million in Series D financing to continue the expansion of its democratized ecosystem, which provides drug developers with open access to foundational antibody discovery platforms and services. This funding supports the company’s commitment to scaling its technology infrastructure, enabling scientific partners to advance biotherapeutic pipelines from discovery to the clinic. — […]
ATX-Gx™ Biotech Licensee Discovering Novel Therapeutics
Dren Bio leveraged Alloy Therapeutics’ ATX-Gx™ humanized mouse platform and Discovery Services to successfully identify a high-quality lead candidate for its Enhanced ADCC Program. This partnership underscores the effectiveness of Alloy’s royalty-free licensing model and integrated discovery support in helping biotech startups rapidly advance oncology and autoimmune programs toward the clinic. Alloy has more than […]
How Alloy is Enabling the Discovery and Engineering of Chimeric Antigen Receptors for Cell Therapies
Alloy Therapeutics enables high-throughput CAR discovery and engineering by providing diverse binder sets from its ATX-Gx™ and ATX-SiD platforms to optimize antigen specificity and affinity. Their Discovery Services offer comprehensive functional screening in primary immune cells—including expression, activation, and cell-killing assays—to streamline the development of next-generation CAR-T, NK, and macrophage therapies. Cell therapy utilizing chimeric […]
How Enabling Drug Delivery Innovation Gets Better Medicines to Patients
Alloy Therapeutics is democratizing access to foundational drug delivery, formulation, and half-life extension technologies to overcome critical barriers such as molecular stability and crossing the blood-brain barrier. Through its Innovation Subscription model and collaborations with institutions like MIT’s Marble Center, Alloy provides the drug discovery community with validated, pre-competitive delivery platforms including LNPs and antibody-drug […]
How Alloy is Democratizing T Cell Receptor (TCR) Therapy Discovery
At Alloy Therapeutics our goal is to empower drug discovery teams with technologies and services enabling them to make the best medicines for patients. Our company started this work in antibodies with a long-term plan to expand innovation to “adjacent modalities” that require similar expertise and could leverage much of our core antibody discovery, protein […]
How Our Mytide Investment Supports the Peptides Ecosystem
Peptides are a promising therapeutic modality in that they are small and specific in their targeting, while being relatively inexpensive to manufacture. Insulin is perhaps the best-known therapeutic peptide, but since 2000 33 non-insulin peptide therapeutics have been approved, spanning treatments for HIV, chronic pain, metabolic disease, cancer, cardiovascular disease, and more. Improvements in production, […]